retatrutide type 2 diabetes phase 2 results 2024 Eli Lilly just announced striking 3 for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% New clinical trial results show

With ultra-high polyphenol oils exceeding 2,000 mg/kg, a daily serving of 5 ml can provide equivalent or greater polyphenol intake

Retatrutide is an investigational triple GLP-1/GIP/glucagon receptor agonist not approved by the MHRA or EMA

Frequently Asked Questions Why does retatrutide cause sulphur burps

Alcohol consumption was already declining

Retatrutide (also known by its lab name LY3437943) works by activating three gut hormone receptors at once: GLP-1, GIP, and glucagon

read time: 4 min Health & Wellness Semaglutide (GLP-1 receptor agonist) medications, marketed under names such as Ozempic and Wegovy , have made their way to your local pharmacy